Rapid detection of bacteria and viruses: justification, regulation, requirements and technologies – how can industry achieve broad adoption?

23 September 2019
Technology Strategy
Rapid detection of bacteria and viruses: justification, regulation, requirements and technologies - how can industry achieve broad adoption?
379.82 KB

One of the main targets for BioPhorum Technology Roadmapping is to reduce the testing times for bacteria (including mycoplasma), fungi and viruses in biological therapeutics from four weeks to just one or two days. It has made significant progress on understanding the challenges to achieving this goal, which are captured in the publication of the white paper Rapid detection of bacteria and viruses in bioprocess samples: justification, regulation, requirements and technologies – how can industry achieve broad adoption

The paper addresses the main factors preventing the use of alternative rapid microbiology methods (RMM) for testing to assure sterility and the absence of adventitious agents in the manufacturing process. Ultimately, it aims to move the industry towards the real-time release of drug products.

The project evolved out of the first edition of BioPhorum’s BioManufacturing Technology Roadmap. “One of the biggest desires from biomanufacturers was to shorten the testing time for release,” explained Audrey Chang, Head of Process Solution Services R&D at Merck. “Our group came together to ask, ‘What can we do to move towards that vision?’

“We recognized that implementing these newer technologies in a regulated environment is challenging, [in particular] demonstrating how they are at least equal to, if not better than, current methods. And so, we thought that if we could share this burden of validation as an industry, we could all benefit.”


Realizing that the scope of the initiative was huge, the workstream (comprising nine biomanufacturers, three supply partners and an innovation hub), quickly established a need to split the project into phases.

Phase 1 was the white paper, aimed at identifying the barriers, listening to end-users and finding ways to resolve those barriers. To achieve these goals, the team conducted a survey, which found that the overwhelming barrier cited was one of regulatory acceptance.

“We’ve got a whole new dawn of medical treatments,” said Morven McAlister, Senior Director, Regulatory & Validation Consultancy at Pall Biotech, “and these new technologies will need these rapid methods. There’s no way we can fully realize their potential if we don’t implement them. We’d like to be able to tie these to existing products as well.”

The survey also revealed the need for what McAlister calls “a playbook”—a guidance document that gives end-users “a tool that will help them understand what they need to do to qualify and validate these alternative rapid micro methods.”

Also, the costs and time associated with manufacturing and filing post-approval changes were raised as concerns. However, one key factor should also not be overlooked, added McAlister. “This wonderful collaboration is all going towards safety in trying to get drugs to the patient faster. It’s not just a case of reducing manufacturing costs, it is ultimately about patient safety.”

Three milestones

A key moment for the workstream came in October 2018 when, as part of a wider BioPhorum microbial control group, it met with the FDA.

Chang explained that today, companies approach the regulators individually with their method validation studies. In this manner, regulators view similar studies in a siloed approach. A more preferable approach would be a shared method validation, where comments and best practices would benefit both industry and regulators.

The discussions were extremely fruitful. “The take-home message for us was that [the FDA] were not only open to our group and what we were trying to do, they encouraged it,” said Chang.

According to Chang, this shows the power of BioPhorum and the feedback from the FDA was that “they really liked the fact that we went not as individual companies but as part of BioPhorum and we represented a consensus viewpoint.”

The project’s second key achievement was the survey, which showed that the interest and drive to implement RMM was widespread. “It really validated our premise that the low level of adoption was not related to a particular method or particular instrument” said Chang. “People recognized that they wanted to implement this and the roadblock was really more of a need for a procedure as to how do we move forward.”

According to Scott Hooper, Associate Director Microbiology at Merck Inc Kenilworth, NJ, the third triumph will be realized once the white paper is published as it will “give people a framework to deal with the barriers, not all of which are technical. There are a lot of different things that we have touched upon in the paper and I think it will provide the tools to move those forward.”

Next steps

“The next stage is to really understand what we have to do to come up with the playbook,” said McAlister. “This will also have regulatory input, which is important. Many others have come up with papers on how to qualify and validate such methods, but this one—because of the collaboration involved between end-users, suppliers, labs and regulators—will be a really powerful document for the industry.”

Phase 2 will see the team develop user requirement specifications to help guide vendors for technology development in this area.

“This paper defines the problem, but there’s a lot of things we want to do in terms of developing solutions and then, of course, implementation,” added Chang, who sees the initiative being a multi-year project—but one that will beat the 10-year timescale set out in the BioPhorum Roadmap.

For more information, contact the Phorum Facilitator Bela Green on

abstract yellow and green patterns
Is it time we revisit regulatory expectation that we obtain microbial identifications when using a non-growth-based monitoring method?
Microbes In Petri Dish
A nine-step framework for evaluating alternative adventitious agent testing
Green And Yellow DNA Chains
Adopting BFPC systems: how BioPhorum is increasing the pace of change
Adding Liquid To Petri Dish
How successfully implementing alternative sterility tests can achieve a ~50% reduced incubation time
Arrows 7 DNA on black background
The M3 Collaboration – bringing together experts in Modern Micro Methods

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
Delivering a Cell and Gene Therapy Outbound Supply Chain Pathway for the Industry
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
A major milestone – a harmonized approach to product carbon footprint data
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing